|
Open Access-Title
|
The role of Notch 2 in primary human breast epithelial cells: a preliminary ex vivo study |
|
|
Author
|
Alexios- Fotios A. Mentis, Panagiotis Tsikouras, Panagiotis Peitsidis, Stefanos Zervoudis University Research Institute of Maternal and Child Health and Precision Medicine, UNESCO Chair on Adolescent Health Care, National and Kapodistrian University of Athens (NKUA), GR-11527 Athens, Greece |
|
|
Citation
|
A-F. A. Mentis, P. Tsikouras, P. Peitsidis, S. Zervoudis. The role of Notch 2 in primary human breast epithelial cells: a preliminary ex vivo study. Review Clin. Pharmacol. Pharmacokinet. 2021, 35, 3, 123-134 |
|
|
Publication Date
Republication Date
|
15-12-2021
27-10-2021
|
|
|
Full Text Language
|
English |
|
|
Keywords
|
Breast cancer; Notch receptor; molecular biology; oncology; metastasis; extracellular matrix
|
|
|
Other Terms
|
Original Study |
|
|
Summary
|
Breast cancer represents a major form of cancer affecting around one out of eight women in resource-rich countries. A hallmark of cancer, including breast cancer, is the dysregulation of intracellular signalling, a notably example of which is the family of Notch (Notch 1 to 4) receptor. While the effects of Notch 1 intracellular signalling have been significantly studied in breast cancer, those of Notch 2, −which shares 37% similarity to Notch1 receptor−, remain far from completely understood. Here, we studied Notch 2 intracellular signalling in human primary breast epithelial cells. Our results showed that: a) Notch 2 signalling may activate different transcription factors than Notch 1 signalling does, b), Notch 2 signalling causes downregulation of ΔΝp63 expression levels, and c) Notch 2 signalling causes distinct changes in the expression levels of integrin proteins in our samples examined. Therefore, if the differences in Notch 1 and Notch2 result in distinct genetic or phenotypic signatures, −an issue to be verified in future studies−, it could be anticipated that targeting Notch 1 and Notch 2 with specific antibodies might lead to distinct therapeutic approaches. | |
| References | 1. Rojas K., Stuckey A.: Breast cancer epidemiology and risk factors. Clin Obstet Gynecol. 59(4):651-72 (2016). 2. Hanahan D., Weinberg R.A.: Hallmarks of cancer: the next generation. Cell. 144(5):646-74 (2011). 3. Mentis A.-F.A., Kararizou E.: Metabolism and cancer: an up-to-date review of a mutual connection. Asian Pac J Cancer Prev. 11(6):1437-44 (2010). 4. Gyparaki M.T., Basdra E.K., Papavassiliou A.G.: MicroRNAs as regulatory elements in triple negative breast cancer. Cancer Lett. 354(1):1-4 (2014). 5. Karamouzis M.V., Papavassiliou A.G.: Transcription factor networks as targets for therapeutic intervention of cancer: the breast cancer paradigm. Mol Med. 17(11-12):1133-6 (2011). 6. Karamouzis M.V., Papavassiliou K.A., Adamopoulos C., Papavassiliou A.G.: Targeting Androgen/Estrogen Receptors Crosstalk in Cancer. Trends Cancer. 2(1):35-48 (2016). 7. Zoi I., Karamouzis M.V., Adamopoulos C., Papavassiliou A.G.: RANKL Signaling and ErbB Receptors in Breast Carcinogenesis. Trends Mol Med. 22(10):839-50 (2016). 8. Artavanis-Tsakonas S., Rand M.D., Lake R.J. Notch signaling: cell fate control and signal integration in development. Science. 284(5415):770-6 (1999). 9. Guruharsha K., Kankel M.W., Artavanis-Tsakonas S.: The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet. 13(9):654-66 (2012) 10. Hori K., Sen A., Artavanis-Tsakonas S.: Notch signaling at a glance. J Cel Sci. 126(10):2135-40 (2013). 11. Vlachakis D., Papageorgiou L., Papadaki A., Georga M., Kossida S., Eliopoulos E.: An updated evolutionary study of the Notch family reveals a new ancient origin and novel invariable motifs as potential pharmacological targets. PeerJ. 8:e10334 (2020). 12. Kandasamy K., Mohan S.S., Raju R., Keerthikumar S., Kumar G.S.S., Venugopal A.K., et al.: NetPath: a public resource of curated signal transduction pathways. Genome Biol. 11(1):1-9 (2010). 13. Papavassiliou A.G..: Molecular medicine. Transcription factors. N Engl J Med. 332(1):45-7 (1995). 14. Polychronidou E., Vlachakis D., Vlamos P., Baumann M., Kossida S.: Notch signaling and ageing. GeNeDis 2014. p. 25-36 (2015). 15. Kourtis N,, Lazaris C., Hockemeyer K., Balandrán J.C., Jimenez A.R., Mullenders J., et al.: Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia. Nat Med. 24(8):1157-66 (2018). 16. Paraskevopoulou V., Bonis V., Dionellis V.S., Paschalidis N., Melissa P., Chavdoula E., et al.: Notch controls urothelial integrity in the mouse bladder. JCI insight 5(3) (2020). 17. Restivo G., Nguyen B.C., Dziunycz P., Ristorcelli E., Ryan R.J., Özuysal Ö.Y., et al.: IRF6 is a mediator of Notch pro‐differentiation and tumour suppressive function in keratinocytes. The EMBO journal. 30(22): 4571-85 (2011). 18. Fu N.Y., Nolan E., Lindeman G.J., Visvader J.E.: Stem cells and the differentiation hierarchy in mammary gland development. Physiological Rev. 100(2):489-523 (2020). 19. Nandi A., Chakrabarti R.: The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance. Genes Dev. 34(21-22):1422-38 (2020). 20. Chakrabarti R., Celià-Terrassa T., Kumar S., Hang X., Wei Y., Choudhury A., et al.: Notch ligand Dll1 mediates cross-talk between mammary stem cells and the macrophageal niche. Science 360(6396): eaan4153 (2018). 21. Deshmukh A.P., Vasaikar S.V., Tomczak K., Tripathi S., Den Hollander P., Arslan E., et al.: Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing. Proc Natl Acad Sci USA. 118(19):e2102050118118 (2021). 22. Mentis A.A.: Review of: Notch ligand Dll1 mediates cross-talk between mammary stem cells and the macrophageal niche [cited 2021 28 April 20201]. Available from: https://publons.com/publon/2795023/ (2019). 23. Tanaka R., Tainaka M., Ota T., Mizuguchi N., Kato H., Urabe S., et al.: Accurate determination of S-phase fraction in proliferative cells by dual fluorescence and peroxidase immunohistochemistry with 5-bromo-2′-deoxyuridine (BrdU) and Ki67 antibodies. J Histochem Cytochem. 59(8):791-8 (2011). 24. Ayyanan A., Civenni G., Ciarloni L., Morel C., Mueller N., Lefort K., et al.: Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci USA. 103(10):3799-804 (2006). 25. Mentis A.-F.A., Dardiotis E., Romas N.A., Papavassiliou A.G.: PIWI family proteins as prognostic markers in cancer: a systematic review and meta-analysis. Cell Mol Life Sci. 77(12):2289-2314 (2020). 26. Strati T.-M., Kotoula V., Kostopoulos I., Manousou K., Papadimitriou C., Lazaridis G., et al.: Prognostic subcellular Notch2, Notch3 and Jagged1 localization patterns in early triple-negative breast cancer. Anticancer Res. 37(5):2323-34 (2017). 27. O’Neill C.F., Urs S., Cinelli C., Lincoln A., Nadeau R.J., León R., et al.: Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth. Am J Pathol. 171(3):1023-36 (2007). 28. Stylianou S., Clarke R.B., Brennan K.: Aberrant activation of notch signaling in human breast cancer. Cancer Res. 66(3):1517-25 (2006). 29. Parr C., Watkins G., Jiang W.: The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med. 14(5):779-86 (2004). 30. Fu Y.-P., Edvardsen H., Kaushiva A., Arhancet J.P., Howe T.M., Kohaar I., et al.: NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations. Mol Cancer 9(1):1-11 (2010). 31. Duss S., André S., Nicoulaz A.-L., Fiche M., Bonnefoi H., Brisken C, et al.: An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells. Breast Cancer Res. 9(3): 1-15 (2007). 32. Yalcin-Ozuysal O., Fiche M., Guitierrez M., Wagner K.U., Raffoul W., Brisken C.: Antagonistic roles of Notch and p63 in controlling mammary epithelial cell fates. Cell Death Differ. 17(10):1600-12 (2010). 33. Curtis C.D., Thorngren D.L., Ziegler Y.S., Sarkeshik A., Yates J.R., Nardulli A.M.: Apurinic/apyrimidinic endonuclease 1 alters estrogen receptor activity and estrogen-responsive gene expression. Mol Endocrinol. 23(9):1346-59 (2009). 34. Bertrand F, Eckfeldt CE, Lysholm A, LeBien TW. Notch-1 and Notch-2 exhibit unique patterns of expression in human B-lineage cells. Leukemia. 14(12):2095-102 (2000). 35. Huang C.-H., Chu Y.-R., Ye Y., Chen X.: Role of HERP and a HERP-related protein in HRD1-dependent protein degradation at the endoplasmic reticulum. J Biol. Chem. 289(7):4444-54 (2014). 36. Zine A., Aubert A., Qiu J., Therianos S., Guillemot F., Kageyama R. et al.: Hes1 and Hes5 activities are required for the normal development of the hair cells in the mammalian inner ear. J Neurosci. 21(13):4712-20 (2001). 37. Buono K.D., Robinson G.W., Martin C., Shi S., Stanley P., Tanigaki K., et al.: The canonical Notch/RBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy. Dev Biol. 293(2):565-80 (2006). 38. Tadeu A.M., Horsley V.: Notch signaling represses p63 expression in the developing surface ectoderm. Development. 140(18): 3777-86 (2013). 39. Critchley D.R., Holt M.R., Barry S.T., Priddle H., Hemmings L.,Norman J.: Integrin-mediated cell adhesion: the cytoskeletal connection. In Biochemical Society Symposium (Vol. 65, pp. 79-99) (1999). 40. Hodkinson P.S., Elliott P.A., Lad Y., McHugh B.J., MacKinnon A.C., Haslett C., et al.: Mammalian NOTCH-1 activates beta1 integrins via the small GTPase R-Ras. J Biol. Chem. 282(39): 28991-9001 (2007). 41. Min W., Zou C., Dai D., Zuo Q., Chen C., Xu J., et al.: Integrin Beta 1 Promotes Glioma Cell Proliferation by Negatively Regulating the Notch Pathway. J Oncol. 2020:8297017 (2020). 42. Zheng Y., Cecile C., Sayles L.C., Alleyne-Chin C., Vaka D., Knaak T.D., et al.: A rare population of CD24+ ITGB4+ Notchhi cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. Cancer Cell. 24(1):59-74 (2013). 43. Kraman M., McCright B.: Functional conservation of Notch1 and Notch2 intracellular domains. The FASEB J. 19(10):1311-1313 (2005). 44. Mentis A.A., Boziki M., Grigoriadis N., Papavassiliou A.G.: Helicobacter pylori infection and gastric cancer biology: tempering a double-edged sword. Cell. Mol. Life. Sci. 76(13):2477-86 (2019). 45. Šale S., Lafkas D., Artavanis-Tsakonas S.: Notch2 genetic fate mapping reveals two previously unrecognized mammary epithelial lineages. Nature Cell Biol. 15(5):451-60 (2013). 46. Capulli M., Hristova D., Valbret Z., Carys K., Arjan R., Maurizi A., et al.: Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry. Br J Cancer. 121(2):157-171 (2019). 47. Sehrawat A., Sakao K., Singh S.V.: Notch2 activation is protective against anticancer effects of zerumbone in human breast cancer cells. Breast Cancer Res Treat. 146(3): 543-55 (2014). 48. Kim S.-H., Sehrawat A., Singh S.V.: Notch2 activation by benzyl isothiocyanate impedes its inhibitory effect on breast cancer cell migration. Breast Cancer Res Treat. 134(3):1067-79 (2012). 49. Lee J., Sehrawat A., Singh S.V.: Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells. Breast Cancer. Res. Treat. 136(1):45-56 (2012). 50. Kim S.-H., Hahm E.-R., Arlotti J.A., Samanta S.K., Moura M.B., Thorne S.H., et al.: Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown. Breast Cancer. Res. Treat. 2016;157(1):41-54. 51. Ho R.X.-Y., Meyer R.D., Chandler K.B., Ersoy E., Park M., Bondzie P.A., et al.: MINAR1 is a Notch2-binding protein that inhibits angiogenesis and breast cancer growth. J Mol. Cell. Biol. 10(3):195-204 (2018). 52. Ilhan M., Kucukkose C., Efe E., Gunyuz Z.E., Firatligil B., Dogan H., et al.: Pro-metastatic functions of Notch signaling is mediated by CYR61 in breast cells. Eur J Cell. Biol. 99(2-3):151070 (2020). 53. Lee G.-H., Yoo K.-C., An Y., Lee H.-J., Lee M., Uddin N., et al.: FYN promotes mesenchymal phenotypes of basal type breast cancer cells through STAT5/NOTCH2 signaling node. Oncogene. 37(14): 1857-1868 (2018). 54. Dekkers J.F., van Vliet E.J., Sachs N., Rosenbluth J.M., Kopper O., Rebel H.G., et al.: Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids. Nat Protoc. 16(4):1936-65 (2021). 55. Yen W.-C., Fischer M.M., Axelrod F., Bond C., Cain J., Cancilla B, et al.: Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clinical Cancer Res. 21(9):2084-95 (2015). 56. Hu Z.I., Bendell J.C., Bullock A., LoConte N.K., Hatoum H., Ritch P., et al.: A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Cancer Med. 8(11):5148-57 (2019). |
|
|
Relative Papers
|
Online ISSN 1011-6583
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
• Chemical Abstracts
• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in:
• Chemical Abstracts
• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor
Τι είναι η Review of Clinical Pharmacology and Pharmacokinetics-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς
What is Review of Clinical Pharmacology and Pharmacokinetics-International Edition-Instrunctions to Authors
Άρθρα Δημοσιευμένα στην Review of Clinical Pharmacology and Pharmacokinetics-Διεθνής Έκδοση
Articles Published in Review of Clinical Pharmacology and Pharmacokinetics-International Edition
Συντακτικη Επιτροπή-Editorial Board